Angiotensin-(1-7) receptor Mas is an essential modulator of extracellular matrix protein expression in the heart

Regulatory Peptides

Volumn 175, Issue 1-3, 2012, Pages 30-42

  Gava, Elisandra ^a,d   de Castro, Carlos Henrique ^a,b,d   Ferreira, Anderson J ^a,d   Colleta, Heloísa ^a,d   Melo, Marcos B ^a,d   Alenina, Natalia ^c   Bader, Michael ^c   Oliveira, Laser A ^a   Santos, Robson A S ^a,d   Kitten, Gregory T ^a,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d National Institute of Science and Technology in Nanobiopharmaceutics   (Brazil)

Author keywords

Angiotensin; Connective tissue; Extracellular matrix; Fibrosis; Mas receptor; Renin angiotensin system

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7] RECEPTOR MAS; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 6; FIBRONECTIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE DELETION; HEART ATRIOVENTRICULAR VALVE; HEART ATRIUM; HEART DISEASE; HEART PERFORMANCE; HEART RIGHT VENTRICLE; HISTOLOGY; IMMUNOFLUORESCENCE; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; ANIMALS, NEWBORN; BLOTTING, WESTERN; ECHOCARDIOGRAPHY; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; HEART; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, G-PROTEIN-COUPLED;

MUS;

EID: 84858332279     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.01.001     Document Type: Article

References (53)

1. Robinson T.F., Cohen-Gould L., Factor S.M. Skeletal framework of mammalian heart muscle. Arrangement of inter- and pericellular connective tissue structures. Lab Invest 1983, 49:482-498.
2. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 1989, 13:1637-1652.
3. Burlew B.S., Weber K.T. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin 2000, 18:435-442.
4. Gonzalez A., Lopez B., Querejeta R., Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease?. J Mol Cell Cardiol 2002, 34:1585-1593.
5. Weber K.T., Clark W.A., Janicki J.S., Shroff S.G. Physiologic versus pathologic hypertrophy and the pressure-overloaded myocardium. J Cardiovasc Pharmacol 1987, 10(Suppl 6):S37-S50.
6. Villarreal F.J., Dillmann W.H. Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen. Am J Physiol 1992, 262:H1861-H1866.
7. Brilla C.G., Zhou G., Matsubara L., Weber K.T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994, 26:809-820.
8. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998, 83:1182-1191.
9. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 2003, 100:8258-8263.
10. Freeman E.J., Chisolm G.M., Ferrario C.M., Tallant E.A. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 1996, 28:104-108.
11. Strawn W.B., Ferrario C.M., Tallant E.A. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999, 33:207-211.
12. Machado R.D., Santos R.A., Andrade S.P. Opposing actions of angiotensins on angiogenesis. Life Sci 2000, 66:67-76.
13. Tallant E.A., Ferrario C.M., Gallagher P.E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol 2005, 289:H1560-H1566.
14. Iwata M., Cowling R.T., Gurantz D., Moore C., Zhang S., Yuan J.X., et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 2005, 289:H2356-H2363.
15. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., van Boomsma F., et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002, 105:1548-1550.
16. Ferreira A.J., Jacoby B.A., Araujo C.A., Macedo F.A., Silva G.A., Almeida A.P., et al. The nonpeptide angiotensin-(1-7) receptor Mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol 2007, 292:H1113-H1119.
17. Ferreira A.J., Oliveira T.L., Castro M.C., Almeida A.P., Castro C.H., Caliari M.V., et al. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Sci 2007, 81:916-923.
18. Grobe J.L., Mecca A.P., Mao H., Katovich M.J. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006, 290:H2417-H2423.
19. Grobe J.L., Mecca A.P., Lingis M., Shenoy V., Bolton T.A., Machado J.M., et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007, 292:H736-H742.
20. Der Sarkissian S., Grobe J.L., Yuan L., Narielwala D.R., Walter G.A., Katovich M.J., et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008, 51:712-718.
21. Ferreira A.J., Shenoy V., Yamazato Y., Sriramula S., Francis J., Yuan L., et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009, 179:1048-1054.
22. Yamazato Y., Ferreira A.J., Hong K.H., Sriramula S., Francis J., Yamazato M., et al. Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension 2009, 54:365-371.
23. Shenoy V., Ferreira A.J., Qi Y., Fraga-Silva R.A., Diez-Freire C., Dooies A., et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010, 182:1065-1072.
24. Santos R.A., Castro C.H., Gava E., Pinheiro S.V., Almeida A.P., Paula R.D., et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006, 47:996-1002.
25. Junqueira L.C., Bignolas G., Brentani R.R. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979, 11:447-455.
26. Metzger R., Bader M., Ludwig T., Berberich C., Bunnemann B., Ganten D. Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett 1995, 357:27-32.
27. Klewer S.E., Krob S.L., Kolker S.J., Kitten G.T. Expression of type VI collagen in the developing mouse heart. Dev Dyn 1998, 211:248-255.
28. Walther T., Wessel N., Kang N., Sander A., Tschope C., Malberg H., et al. Altered heart rate and blood pressure variability in mice lacking the Mas protooncogene. Braz J Med Biol Res 2000, 33:1-9.
29. Walther T., Balschun D., Voigt J.P., Fink H., Zuschratter W., Birchmeier C., et al. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem 1998, 273:11867-11873.
30. Walters P.E., Gaspari T.A., Widdop R.E. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 2005, 45:960-966.
31. Castro C.H., Santos R.A., Ferreira A.J., Bader M., Alenina N., Almeida A.P. Evidence for a functional interaction of the angiotensin-(1-7) receptor Mas with AT1 and AT2 receptors in the mouse heart. Hypertension 2005, 46:937-942.
32. Ichihara S., Senbonmatsu T., Price E., Ichiki T., Gaffney F.A., Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 2001, 104:346-351.
33. Flores-Munoz M., Smith N.J., Haggerty C., Milligan G., Nicklin S.A. Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol 2011, 589:939-951.
34. Weber K.T., Sun Y., Katwa L.C., Cleutjens J.P., Zhou G. Connective tissue and repair in the heart. Potential regulatory mechanisms. Ann N Y Acad Sci 1995, 752:286-299.
35. Reddi A.S. Collagen metabolism in the myocardium of normal and diabetic rats. Exp Mol Pathol 1988, 48:236-243.
36. Tschope C., Walther T., Koniger J., Spillmann F., Westermann D., Escher F., et al. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 2004, 18:828-835.
37. Panek A.N., Bader M. Matrix reloaded: the matrix metalloproteinase paradox. Hypertension 2006, 47:640-641.
38. McAnulty R.J., Laurent G.J. Collagen synthesis and degradation in vivo. Evidence for rapid rates of collagen turnover with extensive degradation of newly synthesized collagen in tissues of the adult rat. Coll Relat Res 1987, 7:93-104.
39. Chow A.K., Cena J., Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007, 152:189-205.
40. Imai K., Hiramatsu A., Fukushima D., Pierschbacher M.D., Okada Y. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J 1997, 322(Pt 3):809-814.
41. Parsons S.L., Watson S.A., Brown P.D., Collins H.M., Steele R.J. Matrix metalloproteinases. Br J Surg 1997, 84:160-166.
42. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
43. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991, 5:2145-2154.
44. Vu T.H., Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000, 14:2123-2133.
45. Booz G.W., Baker K.M. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 1995, 30:537-543.
46. Gao X., He X., Luo B., Peng L., Lin J., Zuo Z. Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts. Eur J Pharmacol 2009, 606:115-120.
47. Touyz R.M., He G., El Mabrouk M., Schiffrin E.L. p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension 2001, 37:574-580.
48. Su Z., Zimpelmann J., Burns K.D. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 2006, 69:2212-2218.
49. Giani J.F., Gironacci M.M., Munoz M.C., Turyn D., Dominici F.P. Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity. Exp Physiol 2008, 93:570-578.
50. Sampaio W.O., Henrique de Castro C., Santos R.A., Schiffrin E.L., Touyz R.M. Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension 2007, 50:1093-1098.
51. Gava E., Samad-Zadeh A., Zimpelmann J., Bahramifarid N., Kitten G.T., Santos R.A., et al. Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrol Dial Transplant 2009, 24:1766-1773.
52. Clark M.A., Tallant E.A., Diz D.I. Downregulation of the AT1A receptor by pharmacologic concentrations of Angiotensin-(1-7). J Cardiovasc Pharmacol 2001, 37:437-448.
53. Rabelo L.A., Xu P., Todiras M., Samaio W.O., Buttgereit J., Bader M., et al. Ablation of angiotensin (1-7) receptor Mas in C57Bl/6 mice causes endothelial dysfunction. J Am Soc Hypertens 2008, 2:418-424.